Alpha Teknova, Inc. TKNO
Nasdaq · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 2021-06-25
Alpha Teknova, Inc. statistics & valuation
Market cap$308.3M
P / S7.6×
P / B4.5×
Net margin-42.6%
Return on equity-25.1%
FCF margin-24.2%
Net debt$7.2M
Enterprise value USD$315.5M
Earnings yield EBIT/EV-5.4%
Return on capital-17.7%
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Gross margin | 33.2% | 19.2% | 28.1% | 42.2% | 47.8% | 56.7% |
| Operating margin | -41.9% | -69.3% | -96.9% | -119.9% | -32.5% | 14.9% |
| Net margin | -42.6% | -70.9% | -100.3% | -114.6% | -26.6% | 11.4% |
| FCF margin | -24.2% | -35.8% | -72.9% | -134.1% | -78.5% | -9.5% |
| Return on assets | -16.7% | -22.5% | -28.6% | -31.2% | -5.9% | 5.7% |
| Return on equity | -25.1% | -32.5% | -40.9% | -47.5% | -6.8% | 21.3% |
| Debt / equity | 0.19× | 0.11× | 0.15× | 0.22× | 0.08× | 0.00× |
| Current ratio | 4.58 | 3.82 | 5.14 | 5.62 | 13.07 | 4.14 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.